COYA8:00 AMCoya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meetingcoyatherapeutics.com
COYA8:00 AMCoya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Diseasecoyatherapeutics.com
COYA8:00 AMCoya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension PhaseTrial Start • Phase 2coyatherapeutics.com
COYA8:00 AMCoya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summitcoyatherapeutics.com
COYA7:35 AMCoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatecoyatherapeutics.com
COYA7:30 AMCoya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)coyatherapeutics.com